35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

Company Overview - 35Pharma is a Canada-based, private, clinical-stage biopharmaceutical company focused on developing novel protein-based therapeutics [1][9] - The company's lead candidate, HS235, is designed for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) [1][9] Acquisition Details - GSK plc will acquire 100% of the equity of 35Pharma for $950 million, payable in cash at closing [5] - The acquisition is subject to customary conditions, including regulatory agency clearances in the US and Canada [5] Product Information - HS235 is a potential best-in-class investigational medicine that has completed phase I clinical trials and is set to begin studies in PAH and PH-HFpEF [1][6] - The drug targets the activin receptor signalling pathway, which is clinically validated for PAH treatment, and aims to reduce the risk of bleeding while providing metabolic benefits [2][6] Market Context - Pulmonary hypertension (PH) affects approximately 82 million people globally, with a five-year survival rate of around 50% [2][8] - The global market for PH therapies is projected to reach $18 billion by 2032, with activin signalling inhibitors expected to account for 50% of this market [2] Clinical Benefits - HS235 may offer broad metabolic benefits, including fat-selective weight loss, preservation of lean mass, and improved insulin sensitivity, which are particularly relevant given the high prevalence of obesity and insulin resistance in the PH population [3] Strategic Vision - The acquisition aligns with GSK's strategy to enhance its pipeline with differentiated therapies that address unmet needs in pulmonary hypertension and related chronic diseases [4][10]